Emodin, a compound with acclaimed antidiabetic potential, deteriorates glucose tolerance in obese mice

Abu Eid, S.; Adams, M.; Scherer, T.; Torres-Gómez, H.; Hackl, M.T.; Riedl, R.; Luger, A.; Fürnsinn, C.

doi:10.1007/s00125-016-4046-9

Publication type:	Conference other
Type of review:	Peer review (abstract)
Title:	Emodin, a compound with acclaimed antidiabetic potential, deteriorates glucose tolerance in obese mice
Authors:	Abu Eid, S. Adams, M. Scherer, T. Torres-Gómez, H. Hackl, M.T. Riedl, R. Luger, A. Fürnsinn, C.
et. al:	No
DOI:	10.1007/s00125-016-4046-9
Published in:	Diabetologia
Proceedings:	Abstracts of 52nd EASD Annual Meeting
Volume(Issue):	59
Issue:	Suppl 1
Page(s):	S343
Conference details:	52nd EASD Annual Meeting, Munich, Germany, 12–16 September 2016
Issue Date:	Sep-2016
Publisher / Ed. Institution:	Springer
ISSN:	0012-186X 1432-0428
Language:	English
Subject (DDC):	615: Pharmacology and therapeutics 616: Internal medicine and diseases
Abstract:	Emodin is found in herbal remedies used in Traditional Chinese Medicine. Alongside its undisputed laxative action, emodin has been reported to lower blood glucose in hyperglycaemic rodents. Although purely experimental, these results are heralded in non-scientific (online-) sources to promote sales of emodin-containing herbal products as a natural cure for diabetes. While emodin-induced glucose lowering has been attributed to a surprising multitude of molecular mechanisms (activation of PPARγ, inhibition of 11β-HSD, activation of AMPK, etc.), little effort has been made to sort out, whether emodin merely acts via loss of appetite and body weight.
URI:	https://digitalcollection.zhaw.ch/handle/11475/30073
Fulltext version:	Published version
License (according to publishing contract):	Licence according to publishing contract
Departement:	Life Sciences and Facility Management
Organisational Unit:	Institute of Chemistry and Biotechnology (ICBT)
Appears in collections:	Publikationen Life Sciences und Facility Management

Files in This Item:

There are no files associated with this item.

Show full item record

Abu Eid, S., Adams, M., Scherer, T., Torres-Gómez, H., Hackl, M. T., Riedl, R., Luger, A., & Fürnsinn, C. (2016). Emodin, a compound with acclaimed antidiabetic potential, deteriorates glucose tolerance in obese mice [Conference presentation]. Diabetologia, 59(Suppl 1), S343. https://doi.org/10.1007/s00125-016-4046-9

Abu Eid, S. et al. (2016) ‘Emodin, a compound with acclaimed antidiabetic potential, deteriorates glucose tolerance in obese mice’, in Diabetologia. Springer, p. S343. Available at: https://doi.org/10.1007/s00125-016-4046-9.

S. Abu Eid et al., “Emodin, a compound with acclaimed antidiabetic potential, deteriorates glucose tolerance in obese mice,” in Diabetologia, Sep. 2016, vol. 59, no. Suppl 1, p. S343. doi: 10.1007/s00125-016-4046-9.

ABU EID, S., M. ADAMS, T. SCHERER, H. TORRES-GÓMEZ, M.T. HACKL, R. RIEDL, A. LUGER und C. FÜRNSINN, 2016. Emodin, a compound with acclaimed antidiabetic potential, deteriorates glucose tolerance in obese mice. In: Diabetologia. Conference presentation. Springer. September 2016. S. S343

Abu Eid, S., M. Adams, T. Scherer, H. Torres-Gómez, M.T. Hackl, R. Riedl, A. Luger, and C. Fürnsinn. 2016. “Emodin, a Compound with Acclaimed Antidiabetic Potential, Deteriorates Glucose Tolerance in Obese Mice.” Conference presentation. In Diabetologia, 59:S343. Springer. https://doi.org/10.1007/s00125-016-4046-9.

Abu Eid, S., et al. “Emodin, a Compound with Acclaimed Antidiabetic Potential, Deteriorates Glucose Tolerance in Obese Mice.” Diabetologia, vol. 59, no. Suppl 1, Springer, 2016, p. S343, https://doi.org/10.1007/s00125-016-4046-9.